Tag Archives: Pediatric

Early Intervention in Pediatric Asthma: What Are the Long-Term Effects?

January 25, 2019 Share this content: Pediatric asthma control and pulmonary function should be monitored over time to assess the long-term effects of certain interventions and to minimize the negative outcomes of uncontrolled asthma. Effective management of asthma in childhood could potentially preserve lung function and halt or slow disease progression. Identification of phenotypes specific… Read More »

Sprycel (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Print this page PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for Sprycel ® (dasatinib) tablets to include the treatment of pediatric patients one year of age and older with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in combination with chemotherapy.1 Sprycel… Read More »

Treprostinil May Have Antithrombotic Effect in Pediatric Pulmonary Hypertension

January 09, 2019 Share this content: Compared with healthy controls, all circulating platelet microvesicle subpopulations were significantly higher in untreated patients with PAH. In patients with pediatric pulmonary arterial hypertension (PAH), treatment with treprostinil has demonstrated potential antithrombotic mechanisms of action, including the ability to inhibit circulating platelet microvesicles, according to the results of a… Read More »